Michael Schweizer

Trials

Studies that name Michael Schweizer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov

• Ph2/Ph3
  NCT07852195 · Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer

  ECOG-ACRIN Cancer Research Group · not yet recruiting · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
• Ph2
  NCT07698535 · Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

  University of Washington · recruiting · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
• Ph2
  NCT07592910 · A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

  Prostate Cancer Clinical Trials Consortium · not yet recruiting · Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma) · principal investigator
• Ph2
  NCT07466498 · Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

  Fred Hutchinson Cancer Center · recruiting · Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
• Ph2
  NCT06145633 · Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

  Fred Hutchinson Cancer Center · recruiting · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
• Ph1
  NCT06094842 · Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

  Fred Hutchinson Cancer Center · withdrawn · Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 · principal investigator
• Ph2
  NCT06039371 · Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

  University of Washington · recruiting · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
• Ph2
  NCT04951492 · Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

  University of Washington · terminated · Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma · principal investigator
• Ph1/Ph2
  NCT04639245 · Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

  Fred Hutchinson Cancer Center · terminated · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm · principal investigator
• Ph2
  NCT04336943 · Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

  University of Washington · terminated · Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma · principal investigator
• Ph2
  NCT03999515 · Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

  University of Washington · terminated · Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma · principal investigator
• Ph2
  NCT02966587 · Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

  University of Washington · withdrawn · Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability · principal investigator
• Ph2
  NCT02849990 · A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

  University of Washington · completed · Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7 · principal investigator
• Ph2
  NCT02721979 · Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

  University of Washington · terminated · Prostate Adenocarcinoma · principal investigator
• Ph1
  NCT02532114 · Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

  University of Washington · completed · Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy
  R37CA286450 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2024 to 2026 · $667,980 awarded in 2026
  Grant number is on one of their registry trials

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2019 to 2026
  Named on NCT07852195
• Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)
  P50CA097186 · NCI · FRED HUTCHINSON CANCER CENTER · PI Martin Edwin Gleave · fiscal years 2019 to 2026
  Named on NCT06039371, NCT02532114
• Cancer Center Administration
  P30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2019 to 2026
  Named on NCT02966587, NCT02849990, NCT02721979, NCT02532114